The cardiovascular burden of lupus: A complex challenge

Archives of Internal Medicine

Volumn 163, Issue 13, 2003, Pages 1507-1510

  Schattner, Ami ^a   Liang, Matthew H ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; HYDROXYCHLOROQUINE; PHOSPHOLIPID ANTIBODY;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; INFECTION; MORBIDITY; NOTE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREVALENCE; RISK FACTORS;

EID: 0037480240     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.13.1507     Document Type: Note

References (40)

1. Uramoto KM, Michet CJ, Thumboo J Jr, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999;42:46-50.
2. Jacobsen S, Petersen J, Ullman S, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol. 1999;28:75-80.
3. Trends in deaths from systemic lupus erythematosus-United States, 1979-1998. MMWR Morb Mortal Wkly Rep. 2002;51:371-374.
4. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus: long-term follow up of an inception cohort. Arthritis Rheum. 1995;38:1492-1499.
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center, I: causes of death. J Rheumatol. 1995;22:1259-1264.
6. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513-519.
7. Sturfelt G, Eskilsson J, Nived O, et al. Cardiovascular disease in systemic lupus erythematosus: a study of 75 patients from a distinct population. Medicine (Baltimore). 1992;71:216-223.
8. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-415.
9. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51-60.
10. Sun SS, Shiau YC, Tsai SC, et al. The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology (Oxford). 2001;40:1106-1111.
11. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2957-2963.
12. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:338-346.
13. Bulkley BH, Roberts WC. The heart in SLE and the changes induced in it by corticosteroid therapy. Am J Med. 1975;243-264.
14. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. Lupus. 2000;9:170-175.
15. Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
17. Maxwell SRJ, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J. 1994;70:863-870.
18. Roman MJ, Salmon JE, Sobel R, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol. 2001;87:663-666.
19. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104:1887-1893.
20. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
21. Pineau CA, Gladman DD, Ibanez D, Urowitz MB. Lupus disease activity and coronary artery disease [abstract]. Arthritis Rheum. 2001;44:S287.
22. Violi F, Ferro D, Valesini G, et al. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. BMJ. 1990;300:1099-1102.
23. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
24. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
25. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
26. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc. 2000;75:369-380.
27. Munford RS. Statins and the acute-phase response. N Engl J Med. 2001;344:2016-2018.
28. Khamashta MA, Cerrera R, Asherson PA, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990;335:1541-1544.
29. Hughes GRV. Immunology, lupus and atheroma. Lupus. 2000;9:159-160.
30. Vaarala O. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923-925.
31. Horkko S, Olee T, Mo L, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both β2-glycoprotein 1 and oxidized low-density lipoprotein. Circulation. 2001;103:941-946.
32. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoproein uptake by macrophages. Clin Exp Immunol. 1997;107:569-573.
33. Gordon Pa, George J, Khamashta MA, et al. Atherosclerosis and autoimmunity. Lupus. 2001;10:249-252.
34. Pratico D, Ferro D, Iuliano L, et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood. 1999;93:3401-3407.
35. Salonen JT, Yia-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
36. Puurunen M, Manttari M, Manninen V, et al. Antibodies to oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605-2609.
37. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus. 1996;5:442-447.
38. Vaarala O, Manttari M, Manninen V, et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.
39. Tuhrim S, Rand JH, Wu X-X, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561-1565.
40. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25:213-229.